Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

Bibliography

• Hepatitis C. WHO. 2013. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [Last accessed 17 January 2014]
   Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2013;1:318-27
   Google Scholar
• Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013;164:e305-12
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012;44:49-54
   PubMedGoogle Scholar
• Zampino R CN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 2013;20:517-23
   PubMed Web of Science ®Google Scholar
• Coppola N, De Pascalis S, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013;58(4):748-50
   PubMed Web of Science ®Google Scholar
• Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-12
   PubMed Web of Science ®Google Scholar
• Fusco F, D’Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:15S-20S
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11:1174-80
   PubMed Web of Science ®Google Scholar
• Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13:20-6
   Web of Science ®Google Scholar
• Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepat Mon 2013;13:e8352
   PubMed Web of Science ®Google Scholar
• Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-52
   PubMed Web of Science ®Google Scholar
• Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700
   PubMed Web of Science ®Google Scholar
• Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27:773-7
   PubMed Web of Science ®Google Scholar
• Filippini P, Coppola N, Scolastico C, et al. Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis 2001;28:725-9
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004;32:144-8
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Infez Med 2014;22:11-18
   PubMedGoogle Scholar
• Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005;75:522-7
   PubMed Web of Science ®Google Scholar
• Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013;56:206-12
   PubMed Web of Science ®Google Scholar
• Guadagnino V, Stroffolini T, Caroleo B, et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig Liver Dis 2013;45:403-7
   PubMedGoogle Scholar
• Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26:1006-11
   PubMed Web of Science ®Google Scholar
• Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65:83-4
   PubMed Web of Science ®Google Scholar
• Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology 2013;57:2117-23
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009;46:222-9
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40:110-15
   PubMed Web of Science ®Google Scholar
• Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. In Vivo 2013;27:527-9
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009;43:81-7
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
   PubMed Web of Science ®Google Scholar
• Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
   PubMed Web of Science ®Google Scholar
• Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74:406-13
   PubMed Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87
   PubMed Web of Science ®Google Scholar
• Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-91
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94
   PubMed Web of Science ®Google Scholar
• Takahashi K, Nishida N, Kawabata H, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51:2745-7
   PubMed Web of Science ®Google Scholar
• Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54:887-93
   PubMed Web of Science ®Google Scholar
• Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Fam Community Med 2013;20:35-40
   PubMedGoogle Scholar
• Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int 2009;29:248-52
   PubMed Web of Science ®Google Scholar
• Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75
   PubMedGoogle Scholar
• Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
   PubMed Web of Science ®Google Scholar
• Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-90
   PubMed Web of Science ®Google Scholar
• Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-5
   PubMed Web of Science ®Google Scholar
• Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006;49:6074-86
   PubMed Web of Science ®Google Scholar
• Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38
   PubMed Web of Science ®Google Scholar
• Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16
   PubMedGoogle Scholar
• Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012;12:1471-2334
   Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C. Agency EM. 2013. Available from : http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500155469.pdf [ Last accessed 01 February 2014]
   Google Scholar
• Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. FDA. FDA press release. 2013. Available from : http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htm [ Last accessed 17 January 2014]
   Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of the a new era. Rev Recent Clin Trials 2013; In press
   Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. Hepatology 2013;58:733-4
   Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;21:1391-404
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23:561-71
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
   PubMed Web of Science ®Google Scholar
• Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007;13(43):5673-81
   PubMed Web of Science ®Google Scholar
• Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
   PubMed Web of Science ®Google Scholar
• Ma H, Inocencio N, Leveque V, et al. Different incorporation efficiencies for nucleotide analogs during HCV polymerase RNA synthesis initiation and elongation phases. Antiviral Res 2008;78:A22-3
   Web of Science ®Google Scholar
• Yang PL, Gao M, Lin K, et al. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011;1:607-16
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs 2014;23:719-28
   PubMed Web of Science ®Google Scholar
• Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin Investig Drugs 2010;19:963-75
   PubMed Web of Science ®Google Scholar
• Tse MT. All-oral HCV therapies near approval. Nat Rev Drug Discov 2013;12(6):409-11
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013;14:1161-70
   PubMed Web of Science ®Google Scholar
• Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014;95:78-88
   PubMed Web of Science ®Google Scholar
• Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006;17:79-87
   PubMedGoogle Scholar
• Washington C, Moreira S, Haznedar J, et al. Single-dose pharmacokinetics of the HCV polymerase inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects. Drug Metab Pharmacokinet 2013;10:10
   Google Scholar
• Moreira S, Haznedar J, Marbury TC, et al. The effect of mild to moderate renal impairment on the pharmacokinetics (PK) of the hepatitis c virus (HCV) polymerase inhibitor mericitabine (MCB, RG7128). Hepatology 2011;54:537A-8A
   Web of Science ®Google Scholar
• Moreira S, Levi M, Kulkarni R, et al. No impact of cirrhosis on mericitabine (MCB) pharmacokinetics and early antiviral activity in hepatitis C-infected patients receiving MCB plus peginterferon alfa-2a (40KD)/ribavirin (P/R). Hepatology 2012;56:583A-A
   Web of Science ®Google Scholar
• Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46:862A-3A
   Web of Science ®Google Scholar
• Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with Peg-IFN and ribavirin: interim results of R7128 500mg BID for 28 days. J Hepatol 2008;48:S29
   Web of Science ®Google Scholar
• Guedj J, Dahari H, Shudo E, et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012;55:1030-7
   PubMed Web of Science ®Google Scholar
• Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days. Hepatology 2008;48:1024A-A
   Web of Science ®Google Scholar
• Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response (SVR) following RG7128 1500mg bid/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J Hepatol 2010;52:S16
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Jensen D, Herring R Jr, et al. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 2013;58:524-37
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Jensen D, Tsai N, et al. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 2013;58:514-23
   PubMed Web of Science ®Google Scholar
• Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014;209:668-75
   PubMed Web of Science ®Google Scholar
• Gane EJ, Roberts SK, Stedman CAM, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
   PubMed Web of Science ®Google Scholar
• Le Pogam S, Yan JM, Chhabra M, et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother 2012;56:5494-502
   PubMed Web of Science ®Google Scholar
• Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010;202:1510-19
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Hepatology 2012;56:231A-2A
   Web of Science ®Google Scholar
• Jensen DM, Brunda M, Elston R, et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: interim SVR4 results from the ANNAPURNA study. Hepatology 2013;58:741A
   Web of Science ®Google Scholar
• Vere Hodge RA. Meeting report: 26th International Conference on Antiviral Research. Antiviral Res 2013;100:276-85
   PubMed Web of Science ®Google Scholar
• Tan H, Deval J, Kang H, et al. Preclinical characterization of ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C. Hepatology 2012;56:1069A-70A
   Web of Science ®Google Scholar
• Tan H, Jekle A, Kang H, et al. In vitro resistance to ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C. J Hepatol 2013;58:S496
   Web of Science ®Google Scholar
• Tan H, Kang H, Moy C, et al. Analysis of ALS-2200, a novel potent nucleotide analog, combination drug interactions in the hepatitis C virus (HCV) subgenomic replicon system. Hepatology 2012;56:1072A-A
   Web of Science ®Google Scholar
• Marcellin P, Popa S, Berliba A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naive genotype 1 (GT1) patients. Hepatology 2012;56:235A-A
   Web of Science ®Google Scholar
• Marcellin P, Popa S, Streinu-Cercel A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naive patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C. J Hepatol 2013;58:S355
   Google Scholar
• Tan H, Deval J, Kang H, et al. VX-135, a potent single diastereomer of ALS-2200, for the treatment of chronic hepatitis C. J Hepatol 2013;58:S495
   PubMed Web of Science ®Google Scholar
• Popa S, Berliba A, Ghicavii N, et al. VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients with genotype 1 HCV. Hepatology 2013;58:745A
   Web of Science ®Google Scholar
• McGuigan C, Madela K, Aljarah M, et al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 2010;20:4850-4
   PubMed Web of Science ®Google Scholar
• Vernachio JH, Bleiman B, Bryant KD, et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2’-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 2011;55:1843-51
   PubMed Web of Science ®Google Scholar
• Li W, Gao M, Hall A, et al. In vitro characterization of the combination of daclatasvir, an NS5A inhibitor, and BMS-986094 (INX-08189), a precursor to an NS5B inhibitor. Hepatology 2012;56:1074A-5A
   PubMed Web of Science ®Google Scholar
• Patti J, Matson M, Boehlecke B, et al. A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects. J Hepatol 2011;54:S187
   PubMed Web of Science ®Google Scholar
• Campaneria R, Barry AN, Patti J, et al. Evaluation of potential pharmacokinetic drug-drug interaction between BMS-986094 (INX-08189) and verapamil when coadministered in healthy subjects. Hepatology 2012;56:1074A-A
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Hazan L, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients. Hepatology 2011;54:535A-A
   Web of Science ®Google Scholar
• Lawitz E, Lalezari J, Freilich B, et al. BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in increased rates of rapid virologic response (RVR) and eRVR in treatment-naive HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: week 12 results. Hepatology 2012;56:566A-7A
   Web of Science ®Google Scholar
• Cho A, Zhang L, Xu J, et al. Discovery of GS-6620: C-nucleoside HCV polymerase inhibitor [Abstract MEDI 21]. Abstracts of Papers of the American Chemical Society 2012; 244th National Meeting and Exposition
   Google Scholar
• Ray AS, Feng JY, Wang T, et al. GS-6620: a liver targeted nucleotide prodrug with potent pan-genotype anti-hepatitis C virus activity in vitro. J Hepatol 2011;54:S487
   Web of Science ®Google Scholar
• Fenaux M, Cheng G, Mabery E, et al. GS-6620, a novel anti-hepatitis C virus nucleotide prodrug, has a high barrier to resistance in vitro. J Hepatol 2011;54:S476
   Web of Science ®Google Scholar
• Cheng G, Fenaux M, Mabery E, et al. Nucleotide inhibitor resistance selections using GT2A infectious virus: PSI-7851 and GS-6620 select for a novel resistance pathway including substitutions of M289V/L followed by S282T. J Hepatol 2011;54:S473
   Web of Science ®Google Scholar
• Feng JY, Cheng G, Perry J, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent c-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 2014;13:13
   Google Scholar
• Lawitz E, Hill J, Marbury T, et al. GS-6620, a liver-targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects. J Hepatol 2012;56:S470-S71
   Web of Science ®Google Scholar
• Murakami E, Wang T, Babusis D, et al. Metabolism and pharmacokinetics of the anti-HCV nucleotide prodrug GS-6620. Antimicrob Agents Chemother 2014;13:13
   Google Scholar
• Yang W, Wiles J, Patel D, et al. Preclinical characteristics of ACH-3422: a potent uridine nucleotide prodrug for inhibition of hepatitis C virus polymerase. Hepatology 2013;58:436A
   Web of Science ®Google Scholar
• Vajda EG, Marschke KB, Henderson I, et al. Discovery and preclinical profiling of LG-7501, a liver-targeted hepatitis C virus (HCV) nucleotide NS5B polymerase inhibitor designed to improve clinical efficacy and safety. Hepatology 2012;56:1080A-A
   Web of Science ®Google Scholar
• Vajda EG, Marschke KB, Zhi L. HepDirect (TM) improves liver-targeting of HCV nucleotide NS5B polymerase inhibitor LG-7501 versus phosphoramidate pronucleotide technology. J Hepatol 2013;58:S498-S99
   Web of Science ®Google Scholar
• Owens CM, Rhodin MHJ, Polemeropoulos A, et al. Antiviral activity of EP-NI266, a potent nucleotide HCV polymerase inhibitor. J Hepatol 2012;56:S475-S76
   Web of Science ®Google Scholar
• Lawitz EJ, Rodriguez-Torres M, Denning J, et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). J Viral Hepat 2013;20:699-707
   PubMed Web of Science ®Google Scholar